37 results about "Post menopausal osteoporosis" patented technology

The invention discloses an extraction method and the application of an urogenic stem cell exosome. The extraction method comprises the following specific steps: firstly, collecting urine, then carrying out first-time centrifugation, and adding PBS into a first residual liquid obtained after supernatant is removed; carrying out second-time centrifugation, resuspending the second-time residual liquid obtained after the supernatant is removed through a primary culture medium to obtain urogenic stem cell suspension solution; secondly, carrying out multiplication culture on the urogenic stem cellsand passing down to the second to the sixth generation for later use; thirdly, changing the culture medium obtained in the second step, then continuously culturing, collecting and culturing supernatant, centrifuging, filtering and carrying out centrifugal concentration; adding an exosome extraction reagent for extracting to obtain a resuspension solution of the urogenic stem cells. The urogenic stem cell exosome extracted by the invention is proved by animal experiments to have the advantages of good therapeutic effects on senile osteoporosis, postmenopausal osteoporosis and disuse osteoporosis.

A method for the prevention or treatment of postmenopausal osteoporosis by initiating the treatment with a low dose of an estrogenic compound and increasing the dose of the estrogenic compound after the initiation period.

The invention discloses a method for preparing a medicine composition for treating female postmenopausal osteoporosis and relates to the technical field of traditional Chinese medicine. The medicine composition is prepared from raspberries, rhizoma atractylodis macrocephalae, radix paeoniae alba, polygonum multiflorum, jujube kernels, angelica sinensis, codonopsis pilosula, morinda officinalis, acanthopanax, Chinese yam, poria cocos, radix rehmanniae preparata, kudzu vine roots, eucommia ulmoides, mint, polygonatum kingianum, glossy privet fruits, herba epimedii, fructus lycii, cornus officinalis, calcium lactate, semen cuscutae, bovine-derived bone, rhizoma drynariae and liquorice. The medicine composition can increase the bone mineral density of patients suffering from postmenopausal osteoporosis and relieve secondary pains and inflammatory reactions caused by it. Pharmacology experiments and clinical experiments prove that the medicine composition has a remarkable postmenopausal osteoporosis treating effect, and thus having high medical promotion value.

The invention relates to a traditional Chinese medicine composition capable of increasing estrogen. The traditional Chinese medicine composition is prepared from following bulk drugs: honey bran friedwhite peony root, white poria, cassia twig, radix bupleuri, mint, honey bran fried rhizoma atractylodis, Ligusticum wallichii, peeled peach kernel, honey stirred licorice root, oriental waterplantainrhizome, Chinese angelica, tree peony bark, and rhizoma zingiberis. The invention also provides applications of the traditional Chinese medicine composition. The combination of the traditional Chinese medicine composition is appropriate; the traditional Chinese medicine composition is capable of increasing estrogen under the comprehensive effect of the bulk drugs. The traditional Chinese medicinecomposition can be used for treating estrogen related diseases such as climacteric syndrome and postmenopausal osteoporosis.

The present invention is drawn to methods of repairing lytic bone lesions and tumor growth in an individual. In this regard, the present invention discloses use of a Wnt ligand either alone or in combination with anti-Wnt signaling antagonist therapy. The individuals who might benefit from such method may include but are not limited to the ones with multiple myeloma, osteoporosis, post-menopausal osteoporosis, fractures, metastatic breast cancer or metastatic prostate cancer.

The invention discloses a traditional Chinese medicine composition preparation for treating postmenopausal osteoporosis and its preparation and application. The traditional Chinese medicine composition is prepared from raw materials with the following mass proportions: 5-200 parts of centipede seven, 10 parts of Jiaogulan ~300 parts, 10~300 parts of ginseng, 5~200 parts of gardenia. The preparation compatible with the traditional Chinese medicine composition has remarkable effect in treating postmenopausal osteoporosis.

Provided in the present invention is the use of the miR-338 cluster as a marker of postmenopausal osteoporosis. In the present invention, it was found that the miR-338 cluster such as miR-338-3p and / or miR-3065-5p are highly expressed in patients with postmenopausal osteoporosis, and it can be used as a marker of postmenopausal osteoporosis, used for preparing an auxiliary diagnostic kit for postmenopausal osteoporosis, which can specifically detect the expression level of the miR-338 cluster in tissues, and is used for non-invasive and early auxiliary diagnosis of postmenopausal osteoporosis in clinic. In addition, inhibitors of the miR-338 cluster have the efficacy of promoting osteogenesis and can be used for treating or preventing postmenopausal osteoporosis.

The invention provides a traditional Chinese medicine active ingredient composition for treating postmenopausal osteoporosis and application thereof, belonging to the field of medicine. Described traditional Chinese medicine active ingredient formula comprises Chinese medicinal active ingredient Lycium barbarum calculated by weight (mg) ratio (50~350):(6~100):(50~180):(1~10):(10~100) Polysaccharide, Icariin, Polygonin, Quercetin, Danshensu Sodium. The traditional Chinese medicine active ingredient composition of the invention has reasonable compatibility, complements each other, has exact curative effect and strong innovation, and can be effectively applied to the treatment of postmenopausal osteoporosis. After repeated verification, the composition can significantly improve postmenopausal osteoporosis. The model animal has bone mineral density, improves bone microstructure, is safe and effective, and can be used as a long-term drug for postmenopausal osteoporosis. The traditional Chinese medicine composition can be further prepared into a pharmaceutical preparation, the dosage form is small, it is convenient to carry and take, can obtain better economic and social benefits, and has broad application prospects.

The invention relates to a molecular traditional Chinese medicine sustained-release tablet for resisting bone mass loss and a preparation method thereof. The molecular traditional Chinese medicine sustained-release tablet comprises molecular traditional Chinese medicine ingredients and pharmaceutically allowed auxiliary material ingredients, wherein the molecular traditional Chinese medicine components comprise 1-5 parts of specnuezhenide (ligustrum lucidum), 1-5 parts of wedelolactone (eclipta prostrata), 0.5-3 parts of paeoniflorin (peony), 0.5-3 parts of psoralen (psoralea corylifolia), and 1-5 parts of diosgenin (yam) ]; and the auxiliary material ingredients comprise 10-50 parts of sodium alginate, 1-5 parts of carbomer (934) , 10-30 parts of hydroxypropyl methyl cellulose, 10-40 parts of lactose, and 1-5 parts of magnesium stearate. Based on a theory of Chinese medicine and a theory of sustained-release preparations, Chinese medicine pathological features of postmenopausal osteoporosis, and scientific compatibility, the molecular traditional Chinese medicine sustained-release tablet which is safe and reliable, high in bioavailability and significant in curative effect is developed.